The Filing Desk

BioAge Labs

BIOA · Nasdaq · Health Care · Financials, fiscal 2023 to 2025

BIOA · Last close · November 19, 2026
$4.71
Value BioAge Labs yourself

BioAge Labs reported revenue of $9 million in fiscal 2025. Its operating margin was −1,031.5%. Free cash flow was −$82 million. The diluted share count rose 235.0%.

BIOAGE LABS, INC. Latest fiscal year ended December 31, 2025 10-K filed March 24, 2026 · 0001193125-26-120873 Updated
Revenue
$9M
 
Operating margin
−1,031.5%
 
Net income
−$81M
 
Free cash flow
−$82M
 
Return on equity
−27.1%
67.9 pts
Market cap
$216M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What BioAge Labs does

BioAge Labs is a clinical-stage biopharmaceutical company that develops medicines for metabolic diseases by studying the biology of human aging. It has no products approved for sale and has not yet earned revenue from selling any.

Its lead candidate, BGE-102, is a pill designed to block a protein called NLRP3 that drives inflammation. The company plans to test it in cardiovascular risk and in an eye disease called diabetic macular edema. It is also developing candidates that act on the apelin receptor for obesity.

BioAge draws on large sets of data from stored human blood samples and health records, collected over as many as 50 years, to find drug targets. It works with Eli Lilly on earlier-stage programs and with Novartis on finding targets, and it has an option agreement with JiKang Therapeutics for a candidate antibody.

Its biggest risks, as it describes them

  • It has lost money since it began, has no approved products and may never be profitable.
  • Its lead candidate, BGE-102, is early in testing and may not prove safe or effective.
  • It may need more money, which it may not be able to raise on good terms.
  • It depends on partners such as Lilly and Novartis for some programs.
From BioAge Labs's annual report on Form 10-K, filed March 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

BioAge Labs lost money in fiscal 2025: a net loss of $81 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments22354281
Debt incl. finance leases1483
Net debt (negative means net cash)−7−346−278
Net debt to EBITDA———
Debt to equity—0.0x0.0x
Interest coverage−6.2x−33.0x−133.1x
Current ratio0.4x12.9x14.2x
Quick ratio0.4x12.9x14.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project BioAge Labs' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought BioAge Labs shares on the open market, and 4 insiders sold $7.8 million, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jun 30, 2026Shane BartonPrincipal Accounting OfficerSold plan20,216$25.19$509,241Form 4
Jun 29, 2026Shane BartonPrincipal Accounting OfficerSold plan42,350$25.21$1.1 millionForm 4
Apr 1, 2026Paul D RubinChief Medical OfficerSold plan8,820$17.81$157,084Form 4
Mar 2, 2026Paul D RubinChief Medical OfficerSold plan7,433$20.30$150,890Form 4
Feb 2, 2026Paul D RubinChief Medical OfficerSold plan7,433$18.75$139,369Form 4
Jan 13, 2026Kristen FortneyChief Executive Officer, DirectorSold plan233,107$18.12$4.2 millionForm 4
Jan 13, 2026Dov A Md GoldsteinChief Financial OfficerSold plan27,000$19.70$531,844Form 4
Jan 2, 2026Paul D RubinChief Medical OfficerSold plan7,433$12.85$95,514Form 4
Dec 9, 2025Paul D RubinChief Medical OfficerSold plan18,000$12.00$216,000Form 4
Dec 4, 2025Paul D RubinChief Medical OfficerSold plan68,897$10.19$702,060Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score—4 of 8
Rule of 40——
Altman Z''11.9312.64
Accruals ratio−10.2%0.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positiveFailFail
Cash from operations is positiveFailFail
Return on assets rose—Pass
Cash from operations exceeds net incomePassFail
Debt fell relative to assets—Pass
Current ratio rosePassPass
Share count didn't riseFailFail
Gross margin rose——
Revenue rose relative to assets—Pass
F-score—4 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put BioAge Labs side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
BioAge LabsFY25—−1,031.5%−915.5%——4
Innate Pharma SAFY25−55.2%−599.8%−587.4%———Compare
CurisFY25−13.4%−60.5%———3Compare
ProthenaFY25−92.8%−2,216.4%————Compare
Roivant SciencesFY25−71.6%−6,235.7%−9,183.5%−62.6%—1Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue—09
Revenue growth———
Gross profit———
Research and development345974
Operating income−48−78−93
Net income−64−71−81
Diluted EPS (US$)−38.17−6.63−2.24
Diluted shares (millions)21136
Cash flow
Cash from operations−37−52−82
Capital expenditure001
Free cash flow−38−52−82
Dividends paid000
Share buybacks000
Acquisitions000
Stock-based compensation3712
Balance sheet at fiscal year end
Cash and short-term investments22354281
Debt incl. finance leases1483
Total assets26358295
Total liabilities673523
Shareholders' equity−173323272
Margins and ratios
Gross margin———
Operating margin——−1,031.5%
Net margin——−896.1%
Free cash flow margin——−915.5%
Rule of 40 (growth + FCF margin)———
Return on capital———
Return on equity—−95.0%−27.1%
Return on assets—−37.0%−24.7%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: BioAge Labs' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with BioAge Labs.